GlassScriptPhysician profile
Farley K Tumbaco
NPI 1831159102
$2,086.28
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $364 · 2021: $13.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $276.04 | 2019-2020 | |
| Allergan, INC. | $240.50 | 2019-2020 | |
| Lilly USA, LLC | $169.26 | 2019-2020 | |
| Novo Nordisk INC | $167.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.95 | 2019-2020 | |
| Pfizer INC. | $143.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $127.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $113.48 | 2019-2020 | |
| Amarin Pharma, INC. | $98.57 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $94.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $69.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.06 | 2019-2020 | |
| Amgen INC. | $45.67 | 2019-2020 | |
| Shire North American Group INC | $45.35 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.65 | 2019 | |
| Merck Sharp & Dohme LLC | $34.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.87 | 2019 | |
| Genentech USA, INC. | $19.05 | 2019 | |
| Acadia Pharmaceuticals INC | $17.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.67 | 2019 | |
| Abbvie INC. | $13.02 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farley K Tumbaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.